Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Mechanisms underlying synergism between circularized tumor necrosis factor‐related apoptosis inducing ligand and bortezomib in bortezomib‐sensitive or ‐resistant myeloma cells

Published:2022-07-14 Issue:5 Volume:40 Page:999-1008
ISSN:0278-0232
Container-title:Hematological Oncology
language:en
Short-container-title:Hematological Oncology

Author:

Leng Yun¹,Hu Xiaoyan²,Li Lin²,Nkwocha Jewel²,Satta Toshihisa²,Sharma Kanika²,Kmeiciak Maciej²,Zhou Huixing¹,Zhang Zhiyao¹^ORCID,Zhou Liang²,Chen Wenming¹^ORCID,Grant Steven²³^ORCID

Affiliation:

1. Department of Hematology Beijing Chao‐Yang Hospital Capital Medical University Beijing China

2. Division of Hematology/Oncology Department of Medicine Virginia Commonwealth University Richmond Virginia USA

3. Massey Cancer Center Virginia Commonwealth University Richmond Virginia USA

Funder

National Institutes of Health

Publisher

Wiley

Subject

Cancer Research,Oncology,Hematology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/hon.3045

Reference44 articles.

1. AlbagoushSA AzevedoAM.Multiple Myeloma.StatPearls. Treasure Island (FL);2020.

2. Proteasome inhibitor bortezomib for the treatment of multiple myeloma

3. Bortezomib (PS-341): A Novel, First-in-Class Proteasome Inhibitor for the Treatment of Multiple Myeloma and Other Cancers

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Aponermin: First Approval;Drugs;2024-03-05

2. GZ17-6.02 interacts with proteasome inhibitors to kill multiple myeloma cells;Oncotarget;2024-03-05

3. Non-canonical role for the ataxia-telangiectasia-Rad3 pathway in STAT3 activation in human multiple myeloma cells;Cellular Oncology;2023-05-01

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3